Abstract: Enzyme activity is measured promptly with a high accuracy by introducing an enzyme, the activity of which is to be measured, into a column comprising a hollow tube packed with a filler comprising a support and a substrate that can be recognized by the enzyme, which is immobilized on the support, and measuring the amount of the obtained decomposition product of the substrate.

Abstract: The active support substance and the adsorbent for chromatography, which have got all of the properties desired for affinity chromatography, can be constituted by a porous copolymer comprising gel copolymer which is principally composed of (A) a glycidyl monovinylester or glycidyl monovinylether and (B) alkyleneglycol divinylester, and combination groups to be bound to ligands through a covalent bond, the (A) component being crosslinked by the (B) component, and the combination groups being bound to epoxy groups of the (A) component.

Abstract: Disclosed is an adsorbent composed of porous beads of uncrosslinked or crosslinked chitosan, wherein protein A or lectin is covalent-bonded trough a bonding group to the amino group of glucosamine constituting the chitosan in the case of uncrosslinked chitosan or to the amino group of glucosamine constituting the chitosan and an amino group of a crosslinking agent in the case of crosslinked chitosan. The adsorbent composed of the chitosan porous beads to which protein A is bonded through a bonding group is used for absorption removal of interleukin 2 inhibitor. The adsorbent composed of the chitosan porous beads to which lectin is bonded through a combination group is used as an adsorbent for affinity chromatography.An adsorbent composed of porous beads of uncrosslinked or crosslinked chitosan is used for adsorbing immunoglobulin. An adsorbent composed of uncrosslinked or crosslinked chitosan wherein an .omega.

Abstract: A process for the optical resolution of DL-cysteine which comprises(1) converting DL-cysteine into a hydrochloride thereof and forming a saturated or supersaturated aqueous solution thereof,(2) inoculating the solution with crystals of one optically active form of cysteine hydrochloride as seed crystals, and(3) preferentially crystallizing optically the same form of the cysteine hydrochloride used as the seed crystals, in a state of a monohydrate thereof.

Abstract: The 4(3H)-quinazolinone compounds of the formula (I) ##STR1## wherein R.sub.1 and R.sub.3, independently from each other, represent a lower alkyl group;R.sub.2 represents a lower alkoxycarbonyl group;Q represents a phenyl group or a substituted phenyl group substituted by at least one member selected from the group consisting of halogen atoms, lower alkyl groups, lower alkoxy groups, di(lower)-alkylamino groups, a methylenedioxy group, a trifluoromethyl group, a hydroxyl group, and a nitro group;R.sub.4 represents a hydrogen atom or a lower alkyl group;R.sub.

Abstract: A 5,6,7-substituted-2,4(1H,3H)-quinazolinedione compound of the formula (I), ##STR1## wherein R.sub.1, R.sub.2, R.sub.3, A and B are as defined in claim 1 and its acid addition salt; and a vasodilating and hypotensive composition containing the aforesaid compound.

Abstract: A novel production process of .beta.-chloroalanine from chloroacetaldehyde is provided. In this process, a bisulfite or sulfite addition compound of chloroacetaldehyde is first reacted, in an aqueous solution, with ammonia and, then, reacted with hydrocyanic acid or a salt thereof. Thus, .alpha.-amino-.beta.-chloropropionitrile is formed. This .alpha.-amino-.beta.-chloropropionitrile is hydrolyzed under an acidic condition to form .beta.-chloroalanine.